Cas:1081-78-3 a,a-Dimethyl-4-(trifluoromethyl)-Benzeneethanamine-hydrochloride manufacturer & supplier

Chemical Name:a,a-Dimethyl-4-(trifluoromethyl)-Benzeneethanamine-hydrochloride

CAS.NO:1081-78-3

Synonyms:Phenethylamine, α,α-dimethyl-p-(trifluoromethyl)-, hydrochloride (8CI);2-Methyl-1-[4-(trifluoromethyl)phenyl]-2-propanamine hydrochloride (1:1);MFCD01761830;Benzeneethanamine, α,α-dimethyl-4-(trifluoromethyl)-, hydrochloride (1:1)

Molecular Formula:C₁₁H₁₅ClF₃N

Molecular Weight:253.692

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:253.084518

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Phenethylamine, α,α-dimethyl-p-(trifluoromethyl)-, hydrochloride (8CI) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzeneethanamine, α,α-dimethyl-4-(trifluoromethyl)-, hydrochloride (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Phenethylamine, α,α-dimethyl-p-(trifluoromethyl)-, hydrochloride (8CI) Use and application,2-Methyl-1-[4-(trifluoromethyl)phenyl]-2-propanamine hydrochloride (1:1) technical grade,usp/ep/jp grade.

Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? a,a-Dimethyl-4-(trifluoromethyl)-Benzeneethanamine-hydrochloride manufacturer He added that the government raised the travel advice warning to level four, the highest, meaning they’re now advising people not to travel to mainland China. The warning aims to address ��the issue of the human-to-human transmission of the coronavirus.�� a,a-Dimethyl-4-(trifluoromethyl)-Benzeneethanamine-hydrochloride supplier High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies. a,a-Dimethyl-4-(trifluoromethyl)-Benzeneethanamine-hydrochloride vendor The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment. a,a-Dimethyl-4-(trifluoromethyl)-Benzeneethanamine-hydrochloride factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?